カテゴリー： Transparency Market Research, 世界, 医療/バイオ

多発性硬化症治療の世界市場2022～2031：治療薬別、流通チャネル別

◆英語タイトル：Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs and Pipeline Drugs; and Distribution Channel: Retail Pharmacies, E-commerce, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
	◆商品コード：TMR23FB110 ◆発行会社（リサーチ会社）：Transparency Market Research ◆発行日：2022年12月13日 ◆ページ数：100 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,795 ⇒換算￥880,840	見積依頼/購入/質問フォーム
Multi User（5名様閲覧）	USD8,795 ⇒換算￥1,336,840	見積依頼/購入/質問フォーム
Corporate License（法人閲覧）	USD11,795 ⇒換算￥1,792,840	見積依頼/購入/質問フォーム

★Transparency Market Researchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の本調査レポートでは、多発性硬化症治療の世界市場について総合的に分析し、今後の市場動向を予測しています。本書は、序論、仮定・調査方法、エグゼクティブサマリー、市場概要、主要インサイト、治療薬別（承認薬、パイプライン薬）分析、流通チャネル別（小売薬局、Eコマース、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目が整理されています。また、本書内には、F. Hoffmann-La Roche Ltd.、Sanofi、Mapi Pharma Ltd.、Atara Biotherapeutics、Takeda Pharmaceuticals International, Inc.、AB Science、Mallinckrodtなどの企業情報が含まれています。
・序論
・仮定・調査方法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の多発性硬化症治療市場規模：治療薬別
- 承認薬の市場規模
- パイプライン薬の市場規模
・世界の多発性硬化症治療市場規模：流通チャネル別
- 小売薬局チャネルの市場規模
- Eコマースチャネルの市場規模
- その他チャネルの市場規模
・世界の多発性硬化症治療市場規模：地域別
- 北米の多発性硬化症治療市場規模
- ヨーロッパの多発性硬化症治療市場規模
- アジア太平洋の多発性硬化症治療市場規模
- 中南米の多発性硬化症治療市場規模
- 中東・アフリカの多発性硬化症治療市場規模
・競争状況

Primary Progressive Multiple Sclerosis Treatment Market – Scope of Report
TMR’s report on the global primary progressive multiple sclerosis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global primary progressive multiple sclerosis treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global primary progressive multiple sclerosis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the primary progressive multiple sclerosis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global primary progressive multiple sclerosis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global primary progressive multiple sclerosis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global primary progressive multiple sclerosis treatment market.

The report delves into the competitive landscape of the global primary progressive multiple sclerosis treatment market. Key players operating in the global primary progressive multiple sclerosis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global primary progressive multiple sclerosis treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market primary progressive multiple sclerosis treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Key Product/Brand Analysis
5.5. Major Research Institutes Involved
5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2017 – 2031
6.3.1. Approved Drugs
6.3.2. Pipeline Drugs
6.4. Market Attractiveness By Drug Type
7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By Distribution Channel, 2017 – 2031
7.3.1. Retail Pharmacies
7.3.2. E-commerce
7.3.3. Others
7.4. Market Attractiveness By Distribution Channel
8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region
9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Type, 2017 – 2031
9.2.1. Approved Drugs
9.2.2. Pipeline Drugs
9.3. Market Value Forecast By Distribution Channel, 2017 – 2031
9.3.1. Retail Pharmacies
9.3.2. E-commerce
9.3.3. Others
9.4. Market Value Forecast By Country, 2017 – 2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2017 – 2031
10.2.1. Approved Drugs
10.2.2. Pipeline Drugs
10.3. Market Value Forecast By Distribution Channel, 2017 – 2031
10.3.1. Retail Pharmacies
10.3.2. E-commerce
10.3.3. Others
10.4. Market Value Forecast By Country, 2017 – 2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2017 – 2031
11.2.1. Approved Drugs
11.2.2. Pipeline Drugs
11.3. Market Value Forecast By Distribution Channel, 2017 – 2031
11.3.1. Retail Pharmacies
11.3.2. E-commerce
11.3.3. Others
11.4. Market Value Forecast By Country, 2017 – 2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country
12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2017 – 2031
12.2.1. Approved Drugs
12.2.2. Pipeline Drugs
12.3. Market Value Forecast By Distribution Channel, 2017 – 2031
12.3.1. Retail Pharmacies
12.3.2. E-commerce
12.3.3. Others
12.4. Market Value Forecast By Country, 2017 – 2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country
13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2017 – 2031
13.2.1. Approved Drugs
13.2.2. Pipeline Drugs
13.3. Market Value Forecast By Distribution Channel, 2017 – 2031
13.3.1. Retail Pharmacies
13.3.2. E-commerce
13.3.3. Others
13.4. Market Value Forecast By Country, 2017 – 2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Sanofi
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Mapi Pharma Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Atara Biotherapeutics
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Takeda Pharmaceuticals International, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. AB Science
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Mallinckrodt
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis

List of Tables

Table 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 05: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 08: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 14: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 15: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 17: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 多発性硬化症治療の世界市場2022～2031：治療薬別、流通チャネル別(Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs and Pipeline Drugs; and Distribution Channel: Retail Pharmacies, E-commerce, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

多発性硬化症治療の世界市場2022～2031：治療薬別、流通チャネル別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp